| Literature DB >> 34067606 |
Cyrielle Holuka1,2, Chantal J Snoeck3, Sophie B Mériaux1, Markus Ollert4,5, Rejko Krüger6,7, Jonathan D Turner1.
Abstract
Asymptomatic individuals, called "silent spreaders" spread SARS-CoV-2 efficiently and have complicated control of the ongoing COVID-19 pandemic. As seen in previous influenza pandemics, socioeconomic and life-trajectory factors are important in disease progression and outcome. The demographics of the asymptomatic SARS-CoV-2 carriers are unknown. We used the CON-VINCE cohort of healthy, asymptomatic, and oligosymptomatic individuals that is statistically representative of the overall population of Luxembourg for age, gender, and residency to characterise this population. Gender (male), not smoking, and exposure to early-life or adult traumatic experiences increased the risk of IgA seropositivity, and the risk associated with early-life exposure was a dose-dependent metric, while some other known comorbidities of active COVID-19 do not impact it. As prior exposure to adversity is associated with negative psychobiological reactions to external stressors, we recorded psychological wellbeing during the study period. Exposure to traumatic events or concurrent autoimmune or rheumatic disease were associated with a worse evolution of anxiety and depressive symptoms throughout the lockdown period. The unique demographic profile of the "silent spreaders" highlights the role that the early-life period plays in determining our lifelong health trajectory and provides evidence that the developmental origins of health and disease is applicable to infectious diseases.Entities:
Keywords: COVID-19; SARS-CoV-2; adult traumatic events; early-life adversity; psychosocial adversity; relative risk; serology
Year: 2021 PMID: 34067606 PMCID: PMC8157140 DOI: 10.3390/jcm10102159
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Demographics of SARS-CoV-2 IgA seropositivity in asymptomatic or oligosymptomatic individuals. (A) Crude relative risk estimates for SARS-CoV-2 IgA seropositivity for all members of the CON-VINCE cohort finishing the five experimental visits. (B) Sex-adjusted logistic regression relative risk of being SARS-CoV-2 IgA seropositive due to pre-existing comorbidities. Both panels: Circles represent the relative risk (RR); error bars: 95% confidence interval; text: p-value. *, p < 0.05; ***, p < 0.005.
Categorical breakdowns of key demographic covariates.
| Age Category | Total | Female/Male | IgA Positive | RR (95%CI; |
|---|---|---|---|---|
| 18–29 | 150 | 90/59 | 21 (14%) | 1 (–) |
| 30–39 | 260 | 133/128 | 42 (16%) | 1.15 (0.7–1.9; 0.67) |
| 40–49 | 325 | 177/147 | 43 (13%) | 0.94 (0.58–1.53; 0.88) |
| 50–59 | 297 | 156/142 | 34 (13%) | 0.82 (0.49–1.36; 0.45) |
| 60–69 | 272 | 150/123 | 34 (11%) | 0.89 (0.54–1.48; 0.65) |
| 70–79 | 154 | 49/107 | 24 (15.5%) | 1.11 (0.65–1.91; 0.75) |
| BMI Category | ||||
| Underweight | 32 | 26/6 | 5 | 1.12 (0.49–2.58; 0.79) |
| Normal | 614 | 333/281 | 85 | 1 (–) |
| Overweight | 493 | 228/265 | 60 | 0.87 (0.65–1.20; 0.42) |
| Obese | 334 | 170/167 | 49 | 1.05 (0.76–1.46; 0.77) |
| Smoking Category | ||||
| Never smoked | 796 | 444/354 | 120 (15.1%) | 1 (–) |
| Live with smoker | 439 | 180/260 | 58 (13.2%) | 0.89 (0.66–1.17; 0.40) |
| Ex-smoker | 38 | 19/19 | 6 (15.7%) | 1.05 (0.49–2.22; 0.82) |
| Current smoker | 201 | 114/86 | 15 (7.4%) | 0.50 (0.30–0.83; 0.004) |
Number of participants with each of the participant-reported comorbidities.
| Disease Categories | Case Numbers | Female/Male | IgA Positive | |
|---|---|---|---|---|
| Cardiac | 53 | 17/36 | 0.009058 | 7 (13.2%) |
| Hypertension | 269 | 113/156 | 0.008748 | 36 (13.4%) |
| Pulmonary | 35 | 17/18 | 0.8658 | 6 (17%) |
| Liver | 36 | 17/19 | 0.7389 | 2 (5%) |
| Kidney | 13 | 7/6 | 0.7815 | 2 (15%) |
| Rheumatological | 199 | 121/78 | 0.002302 | 20 (10.1%) |
| Autoimmune | 115 | 90/25 | 1.35 × 10−9 | 17 (14.7%) |
| HIV | 6 | 1/5 | 0.1025 | 1 (16%) |
| Cancer | 85 | 38/47 | 0.329 | 12 (14.1%) |
| Haematological | 19 | 11/8 | 0.4913 | 1 (5%) |
| Malnourished | 4 | 2/2 | 1 | 2 (50%) |
| Diabetes (I + II) | 76 | 32/44 | 0.1687 | 9 (11.8%) |
| Transplant | 7 | 3/4 | 0.7055 | 1 (14.3%) |
| Psychiatric | 69 | 45/24 | 0.01529 | 7 (10.1%) |
| Other | 0 | 0/0 | n/a | 0 (0%) |
| CTQ >2 | 18 | 17/1 | 4.56 × 10−10 | 6 (33.3%) |
Figure 2Exposure to early-life adversity is associated with SARS-CoV-2 seropositivity in asymptomatic or oligosymptomatic individuals. (A) ELA is linked to SARS-CoV-2 seropositivity in a dose-dependent manner as the cutoff for being considered subject to ELA increases. The central black line represents the sex-adjusted logistic regression relative risk (RR); the grey shaded area represents the 95% confidence interval; text: p-value. (B) Sex-adjusted logistic regression relative risk of IgA seropositivity for the CTQ subscales identifies physical abuse as a key element of the overall CTQ score contributing to the risk of IgA seropositivity. Circles represent the relative risk (RR); error bars: 95% confidence interval; text: p-value. *, p < 0.05; **, p < 0.01; ***, p < 0.005.
Figure 3Exposure to adult traumatic events (ATE) is linked to IgA seropositivity in asymptomatic or oligosymptomatic individuals. (A) The two principal components after K-means clustering of the responses to the ATE questionnaire identified three clusters of responses. Circles (blue shaded area)—Cluster 1; Triangles (pink shaded area)—Cluster 2; Crosses (red shaded area)—Cluster 3. (B) Sex-adjusted relative risk CTQ subscales identified ATE clusters 2 and 3 (negative and positive salience, respectively) as having a similar effect on SARS-CoV-2 IgA seropositivity. Circles represent the relative risk (RR); error bars: 95% confidence interval; text: p-value. *, p < 0.05.
Figure 4Socioeconomic covariates do not determine SARS-CoV-2 IgA seropositivity in asymptomatic or oligosymptomatic individuals. Sex-adjusted logistic regression relative risk of SARS-CoV-2 IgA seropositive due to current socioeconomic conditions. Circles represent the relative risk (RR); error bars: 95% confidence interval; text: p-value.
Figure 5Psychological response to the containment measures during the study period in healthy, asymptomatic, and oligosymptomatic individuals. (A) Data density plot for the response to the Center for Epidemiologic Studies Depression Scale (CES-D) for the five experimental visits. (B) Significant group differences in CES-D score at the baseline CON-VINCE visit. Full statistical data are included in Supplementary Table S3. Data are from univariate ANOVA analysis, text above/below each bar is the ANOVA p-value. (C) Significant group differences in the change in CES-D score between the baseline and last CON-VINCE visit. Full statistical data are included in Supplementary Table S4. Data are from univariate ANOVA analysis, text above/below each bar is the ANOVA p-value. The full multiparameter ANOVA model is described in the Results Section. (D) Data density plot for the response to the Generalised Anxiety Disorder-7 (GAD-7) questionnaire for the five experimental visits. (E) Significant group differences in GAD-7 score at the baseline CON-VINCE visit. Full statistical data are included in Supplementary Table S4. Data are from univariate ANOVA analysis, text above/below each bar is the ANOVA p-value. (F) Significant group differences in the change in GAD-7 score between the baseline and last CON-VINCE visit. Full statistical data are included in Supplementary Table S4. Data are from univariate ANOVA analysis, text above/below each bar is the ANOVA p-value. The full multiparameter ANOVA model is described in the Results Section.